<DOC>
	<DOCNO>NCT01746784</DOCNO>
	<brief_summary>The purpose study investigate safety , tolerability pharmacokinetics N6022 , obtain descriptive information effect N6022 biomarkers CFTR function inflammation adult cystic fibrosis subject homozygous F508del-CFTR mutation .</brief_summary>
	<brief_title>Safety Pharmacokinetic Study N6022 Subjects With Cystic Fibrosis Homozygous F508del-CFTR Mutation</brief_title>
	<detailed_description>This double-blind , randomize , placebo-controlled , multicenter , sequential dose-escalation study occur two part . All selection criterion , assessment procedure describe protocol applied part . Up 5 cohort study total 67 patient approximately 18 clinical site United States .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Homozygous F508delCFTR gene Sweat chloride ≥ 60 mEq/L quantitative pilocarpine iontophoresis Body weight ≥ 40 kg FEV1 ≥ 40 % predict Oxygen saturation ≥ 90 % breathe ambient air Hematology clinical chemistry blood urine result clinically significant abnormality would interfere study assessment Negative pregnancy test woman child bear potential Sexually active subject child bear potential willing follow contraception requirement Previous enrollment another cohort study . Any acute infection , include acute upper low respiratory infection pulmonary exacerbation require treatment within 4 week Study Day 1 . Any change chronic therapy CF lung disease within 4 week Study Day 1 . Blood hemoglobin &lt; 10 g/dL screening . Serum albumin &lt; 2.5 g/dL screening . Abnormal liver function define ≥ 3 x upper limit normal ( ULN ) three follow : AST , ALT , GGT , ALP , total bilirubin screening . History abnormal renal function ( creatinine clearance &lt; 50 mL/min use CockcroftGault equation ) within year screening . History , include screen assessment , ventricular tachycardia ventricular arrhythmia . History , include screen assessment , prolong QT and/or QTcF interval ( &gt; 450 msec ) . History solid organ hematological transplantation . Intranasal medication change within 14 day prior Study Day 1 Required Use continuous ( 24 hr/d ) nocturnal supplemental oxygen . Concomitant use inhibitor inducer CYP3A4 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>F508del-CFTR</keyword>
	<keyword>N6022</keyword>
	<keyword>S-Nitrosoglutathione</keyword>
</DOC>